Status:
COMPLETED
Atrantil for Intestinal Bacterial Overgrowth
Lead Sponsor:
Northwestern University
Conditions:
Irritable Bowel Syndrome
Bacterial Overgrowth Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intestinal Bacterial Overgrowth (IBO) is a common functional condition due to excessive amounts of bacteria in the gastrointestinal tract. These bacteria ferment ingested food resulting in the product...
Detailed Description
Intestinal microbial overgrowth is associated with multiple gastrointestinal symptoms. Most prevalent are gas-related symptoms (i.e. bloating, distention, increased flatus, constipation) . Intestinal...
Eligibility Criteria
Inclusion
- Participants must be able to provide informed consent
- Participants must be able to attend study visits
- Participants aged 18 years or greater
- Must have a diagnosis of Intestinal Methane Overgrowth based on North American Consensus/American College of Gastroenterology established cutoffs
- Participants must report current symptoms of bloating, distention, abdominal pain, abdominal discomfort and constipation
- Participant must be an established patient at Northwestern Memorial Hospital
Exclusion
- Participants who are already taking Atrantil
- Participants who are pregnant or breast-feeding
- Participants who cannot tolerate or are unwilling to complete a hydrogen-methane breath test at week 4.
- Inability to attend all study visits and complete survey data.
Key Trial Info
Start Date :
September 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 27 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04755673
Start Date
September 18 2020
End Date
September 27 2022
Last Update
January 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern Medicine Digestive Health Center
Chicago, Illinois, United States, 60611